Fatimataha (Talk | contribs) |
|||
Line 48: | Line 48: | ||
<em>Bdellovibrio bacteriovorus</em> is a predatory bacterium that preys on other (Gram-negative) bacterial species (Rendulic et al., 2004). Its enzymes and their mechanisms are being studied in order to better understand the bacterium for future use as a possible therapeutic agent or as a method to penetrate biofilms (Kadouri and O'Toole, 2005; Sockett and Lambert, 2004). Our team was interested in engineering the bacterium to use it (and its enzymes) as a ‘pathogen eating machine’in food processes-for example targeting <em>Clostridium botulinum</em>, which releases the botulinum toxin. On top of it being an interesting species to work on, we had a leading expert on the <em>Bdellovibrio</em> species at our university. However, the main bacterium we were targeting <em>(Clostridium botulinum)</em> is a Gram-positive bacterium so is not recognised by <em>Bdellovibrio</em>. Also, it would take many weeks to engineer <em>Bdellovibrio</em> for single gene mutations, which is difficult to transform using random transposon mutagenesis. This was a project that required many years which our team did not have! | <em>Bdellovibrio bacteriovorus</em> is a predatory bacterium that preys on other (Gram-negative) bacterial species (Rendulic et al., 2004). Its enzymes and their mechanisms are being studied in order to better understand the bacterium for future use as a possible therapeutic agent or as a method to penetrate biofilms (Kadouri and O'Toole, 2005; Sockett and Lambert, 2004). Our team was interested in engineering the bacterium to use it (and its enzymes) as a ‘pathogen eating machine’in food processes-for example targeting <em>Clostridium botulinum</em>, which releases the botulinum toxin. On top of it being an interesting species to work on, we had a leading expert on the <em>Bdellovibrio</em> species at our university. However, the main bacterium we were targeting <em>(Clostridium botulinum)</em> is a Gram-positive bacterium so is not recognised by <em>Bdellovibrio</em>. Also, it would take many weeks to engineer <em>Bdellovibrio</em> for single gene mutations, which is difficult to transform using random transposon mutagenesis. This was a project that required many years which our team did not have! | ||
</p> | </p> | ||
− | <h3>mRNA interference of Streptococcus mutans</h3> | + | <h3>mRNA interference of <em>Streptococcus mutans</em></h3> |
<p> | <p> | ||
− | Streptococcus mutansis one of a number of bacteria involved in tooth decay and is the most prevalent.According to Public Health England, in the UK, ‘almost a quarter (24.7%) of 5 year olds have tooth | + | Streptococcus mutansis one of a number of bacteria involved in tooth decay and is the most prevalent.According to Public Health England, in the UK, ‘almost a quarter (24.7%) of 5 year olds have tooth decay’ of which 3 or 4 teeth are affected. Dental health problems also have a heavy financial burden on the NHS-it spends around £3.4 billion per year on dental care. What makes <em>S. mutans</em> particularly hard to deal wit his its ability to form biofilms regulated by glucosyltransferases which catalyse sucrose to adhesive glucan. In particular, GtfB and GtfB seem to be the most important in biofilm production-mutations in the gtfB and gtfC genes disrupted microcolony formation on saliva coated surfaces(Koo et al., 2010). Our idea was to use a bacteriophage (a virus that only infects bacteria) to deliver micro RNAs or small interfering RNAs to silence those genes. One of our supervisors works with phage so she would be able to guide the wet lab team. We opted to silence the toxins rather than kill the bacteria because we wanted a way of preventing glucan formation without disturbing the balance of the oral microbiome |
</p> | </p> | ||
− | <h3>mRNA interference of Clostridium difficile</h3> | + | <h3>mRNA interference of <em>Clostridium difficile</em></h3> |
<p> | <p> | ||
− | Clostridium difficile is an anaerobic bacterium capable of forming spores (meaning it persists in the environment).Clostridium difficil einfection(CDI) is a major infection which causes hospital and community acquired-diarrhoea.It particularly affects those who have long-term hospital stays (especially the elderly), are immunocompromised/immunodeficient (for example due to chemotherapy) and/or are on broad-spectrum antibiotics. CDI has a heavy financial burden-according to Zhang et al. (2017), the annual costs due to C. difficile infections in the US alone are an estimated $6.3 billion with almost 2.4 million days spent in hospitals.According to the Centers for Disease Control and Prevention, between 1999 and 2007 there was an increase in the | + | <em>Clostridium difficile</em> is an anaerobic bacterium capable of forming spores (meaning it persists in the environment). <em>Clostridium difficil</em> einfection(CDI) is a major infection which causes hospital and community acquired-diarrhoea. It particularly affects those who have long-term hospital stays (especially the elderly), are immunocompromised/immunodeficient (for example due to chemotherapy) and/or are on broad-spectrum antibiotics. CDI has a heavy financial burden-according to Zhang et al. (2017), the annual costs due to <em>C. difficile</em> infections in the US alone are an estimated $6.3 billion with almost 2.4 million days spent in hospitals. According to the Centers for Disease Control and Prevention, between 1999 and 2007 there was an increase in the estimated number of deaths due to CDI from 3,000 to 14,000 which was seen across Europe and Canada as well (McDonaldet al., 2012; Lessa et al., 2012). This has been linked to a hypervirulent, resistance strain of <em>C. difficile</em>. |
− | + | ||
</p> | </p> | ||
<p> | <p> | ||
− | Within the SBRC, our supervisors work with a wide range of Clostridial species in the Clostridia Research Group. Unlike with S. mutans, there was more experience within the team and so the supervisors would be able to work with us more closely and advise us on this project. | + | Within the SBRC, our supervisors work with a wide range of Clostridial species in the Clostridia Research Group. Unlike with <em>S. mutans</em>, there was more experience within the team and so the supervisors would be able to work with us more closely and advise us on this project. |
</p> | </p> | ||
<p> | <p> | ||
− | It was hard to decide between working with Ideonella sakaiensis, Streptococcus mutansor | + | It was hard to decide between working with <em>Ideonella sakaiensis</em>, <em>Streptococcus mutansor</em> and <em>C. difficile</em>. But in the end, the team voted and chose mRNA interference of <em>C. difficile</em> which became our project-<em>Clostridium</em>dTox. |
</p> | </p> | ||
<div class="ui button" onclick="$('.bib').toggle()">Bibliography</div> | <div class="ui button" onclick="$('.bib').toggle()">Bibliography</div> | ||
Line 72: | Line 71: | ||
</div> | </div> | ||
− | <a class="anchor" id="design"></a> | + | <a class="anchor" id="Project design"></a> |
<div class="ui segment"> | <div class="ui segment"> | ||
<h2>Design</h2> | <h2>Design</h2> | ||
− | <h3>C. difficile and Phage Characterisation</h3> | + | <div class="ui divider"></div> |
− | < | + | <h3><em>C. difficile</em> and Phage Characterisation</h3> |
+ | <p> | ||
+ | <em>C. difficile</em> strain SBRC 078 was isolated previously in the SBRC from clinical faecal samples and belongs to the hypervirulent PCR ribotype 078. The strain contains the genes <em>tcdA</em> and <em>tcdB</em> encoding for both toxins. Phage phiSBRC was previously isolated in the SBRC from an environmental sample and can infect and form plaques on <em>C. difficile</em> SBRC 078. A lysogenic version of <em>C. difficile</em> SBRC 078, which contains phage phiSBRC integrated into the bacterial chromosome, was created previously in the SBRC. | ||
+ | </p> | ||
+ | |||
+ | <h4><em>C. difficile</em> growth analysis</h4> | ||
+ | <p> | ||
+ | The growth profile of the wildtype version of <em>C. difficile</em> SBRC 078 was compared to the growth profile of the lysogenic version of this strain. To assess this the growth of both strains was monitored for 24 hours and the OD at 600 nm was measured and the maximum growth rate was calculated using the equation | ||
+ | <center> | ||
+ | (2.303x(log10t2)–(log10t1))/3 | ||
+ | </center> | ||
+ | where t1 is the OD at the start of exponential phase and t2 is the OD at the end of exponential phase. This data was used to inform the model parameters and was required to ensure that in the human gut the lysogenic bacterial strains created in this project would grow in the same manner as the wild-type cells and therefore would outcompete them. | ||
+ | </p> | ||
+ | |||
+ | <h4>Phage burst size</h4> | ||
+ | <p> | ||
+ | Phage burst size was assessed to determine the number of infectious phage particles produced per bacterial cell during one infection cycle. This was determined by measuring the number of infectious phage particles (in plaque forming units per ml) produced over a time-course after infection of <em>C. difficile</em> SBRC 078 with phiSBRC. The titre of free phage at each time point was determined by enumeration of plaques using a plaque assay. <em>C. difficile</em> SBRC 078 was infected to a multiplicity of infection (MOI) of 1. The burst size was calculated as the | ||
+ | Final Phage Titre/(Infection Phage Titre – Titre of Unbound Phages). | ||
+ | This data was used to inform the model parameters. | ||
+ | </p> | ||
+ | |||
<h3>dCas 9</h3> | <h3>dCas 9</h3> | ||
<!-- Replace this with content !--> | <!-- Replace this with content !--> |
Revision as of 00:40, 17 October 2018